Biogen

Forecast & Rating36 analysts currently cover Biogen, with about 66.7% giving a positive rating — meaning they expect the stock to rise. The average price target is $247.32, about 2.6% downside from the current price of $253.84. Price targets range from $175.00 to $310.00 — a wide spread, showing clear disagreement over just how much Biogen can rise. Historically, about 36.9% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Biogen closely still see room for the stock to rise. Data as of Oct 22, 2026; for reference only and not investment advice.